Relay Therapeutics Inc. has disclosed three new programs from its existing preclinical pipeline, including two novel programs from its genetic disease portfolio and a potentially first-in-class NRAS-selective inhibitor.
KRAS is the most commonly mutated oncogene in solid tumors. Mutations are present in about 30% of cases overall, more than 95% of pancreatic cancer cases, and about 40% of colon cancer cases.
University of Basel investigators have reported an association between mutations in the COQ8B gene and nonsyndromic retinitis pigmentosa (RP). RP is a genetically heterogeneous retinal degeneration disorder, which has been found to be associated with mutations in more than 70 genes. However, there are still cases for which no genetic cause has been found.
Nutcracker Therapeutics Inc. has disclosed a new drug candidate for the treatment of B-cell lymphoma – NTX-472 – along with results from in vivo studies performed to evaluate its efficacy in mice and macaques.
Alchemab Therapeutics Ltd. has been awarded a grant of $595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program.
Ovarian cancer stem cells are characterized by high activity of aldehyde dehydrogenase (ALDH) enzyme as well as high expression of CD133 marker, and the combination of both correlates with poor prognosis in patients.
Excessive inflammatory response and endothelial barrier dysfunction are the two major pathophysiological changes in acute respiratory distress syndrome (ARDS). Sphingosine-1-phosphate S1P3 receptor (S1PR3) is a G protein-coupled receptor involved in the regulation of inflammation and vascular barrier function in some diseases, but its function in ARDS is not fully understood.
An experimental drug that restored the normal function of ion channels in Alzheimer's disease (AD) prevented the loss of neurons and reduced the accumulation of amyloid-β (Aβ) plaques and hyperphosphorylated tau formed in this condition. A new class of small molecules, collectively called ReS19-T and developed by scientists at the Belgian biotechnology company Remynd NV, reorganized proteins that modulated calcium channels. Now in the clinical phase, this approach could benefit patients suffering from neurodegenerative disorders.
RSS
